Data integrity issues bedevil Chinese API firm Suzhou Pharmaceutical Technology and Japanese manufacturer Sato Yakuhin; inadequate sterility controls net warning letters for Brazilian firm Antibioticos Do Brasil, and US firms Horizon, Pharm D, and Aplicare; and lack of a functioning quality unit observed at Canadian firm Intega in FDA GMP warning letters issued in December and January.
A slew of significant data integrity problems were found at Suzhou Pharmaceutical Technology Co. Inc., an active pharmaceutical ingredient manufacturer in Suzhou, China, by FDA investigators in a June 2016 inspection.
FDA said in a Jan. 6 warning letter that the company was falsifying its certificates of analysis (CoAs)...